A Phase II study of Concurrent Chemoradiation plus Durvalumab (MEDI4736) followed by Surgery followed by Adjuvant Durvalumab (MEDI4736) in medically operable patients with surgically resectable Stage III (N2) Non-Small Cell Lung Cancer: A Hoosier Cancer Research Network Clinical Trial LUN 17-321

Brief description of study

The purpose of the study is to determine the safety and efficacy of having Durvalumab with concurrent chemoradiation followed by surgery in patients with surgically resectable, medically operable stage IIIA NSCLC. We want to know if neoadjuvant Durvalumab will improve patients' responses to therapy when incorporated with chemoradiation prior to surgery.




If you are registered as a volunteer, please login to the dashboard to send referrals.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.